JRCT ID: jRCT1062260006
Registered date:09/04/2026
HiSCO-15A study
Basic Information
| Recruitment status | Recruiting |
|---|---|
| Health condition(s) or Problem(s) studied | Rectal Cancer |
| Date of first enrollment | 09/04/2026 |
| Target sample size | 37 |
| Countries of recruitment | |
| Study type | Interventional |
| Intervention(s) | After abdominoperineal resection, the perineal wound is closed using a semi-closure technique. On postoperative day 1, a negative pressure wound therapy (NPWT) device is applied to the perineal wound. A dressing material is applied to the wound, and negative pressure is initiated. |
Outcome(s)
| Primary Outcome | Incidence of perineal surgical site infection (SSI) within 30 days after surgery |
|---|---|
| Secondary Outcome | 1,Overall incidence of surgical site infection (SSI) 2,Incidence of SSI by anatomical site (Superficial, Deep, Organ/Space) 3,Length of hospital stay 4,Postoperative complications (Clavien-Dindo classification) 5,Causative pathogens of surgical site infection 6,Incidence of skin disorders associated with negative pressure wound therapy (NPWT) |
Key inclusion & exclusion criteria
| Age minimum | >= 18age old |
|---|---|
| Age maximum | Not applicable |
| Gender | Both |
| Include criteria | (1) Patients scheduled to undergo abdominoperineal resection (APR) for colorectal surgery. (2) Patients diagnosed with colorectal cancer histologically according to the "Japanese Classification of Colorectal, Appendiceal, and Anal Carcinoma (9th Edition)," who have received preoperative radiotherapy and are scheduled for Negative Pressure Wound Therapy (NPWT). (3)/(4) Patients aged 18 years or older who have provided written informed consent prior to study enrollment. |
| Exclude criteria | (1) Patients with contaminated perineal wounds accompanied by active infection. (2) Patients with known hypersensitivity to chemical substances (e.g., urethane, polyvinyl alcohol, acrylic adhesives). (3) Patients with comorbid psychiatric disorders that may interfere with the evaluation of the efficacy and safety of this study. (4) Other patients judged by the investigator or sub-investigator to be unsuitable for participation in the study. |
Related Information
| Primary Sponsor | Ohdan Hideki |
|---|---|
| Secondary Sponsor | |
| Source(s) of Monetary Support | Hiroshima Surgical study group of Clinical Oncology |
| Secondary ID(s) |
Contact
| Public contact | |
| Name | Manabu Shimomura |
| Address | 1-2-3 Kasumi, Minami-ku, Hiroshima city, Hiroshima JAPAN Hiroshima Japan 734-8551 |
| Telephone | +81-82-257-5222 |
| mshimo@hiroshima-u.ac.jp | |
| Affiliation | Hiroshima University Hospital |
| Scientific contact | |
| Name | Hideki Ohdan |
| Address | 1-2-3 Kasumi, Minami-ku, Hiroshima city, Hiroshima JAPAN Hiroshima Japan 734-8551 |
| Telephone | +81-82-257-5222 |
| hohdan@hiroshima-u.ac.jp | |
| Affiliation | Hiroshima University Hospital |